Tissue plasminogen activator treatment of experimental subretinal hemorrhage.
Previous investigators have suggested that subretinal blood damages the retina in part because of its solid fibrin meshwork. The role of fibrinolysis in facilitating the clearance of subretinal hemorrhage and preventing degeneration of the overlying retina was studied. Autologous whole blood (0.1 ml) was injected into the subretinal space of 20 rabbits. Twenty-four hours later, the animals were randomized to subretinal treatment with 2.5 micrograms of tissue plasminogen activator or a similar volume of physiologic saline. Mean subretinal hemorrhage thickness 3 days after treatment had decreased to 42% of pretreatment thickness in treated eyes and remained unchanged in control eyes (P less than 0.0005). By 7 days mean clot thickness was 9% in treated eyes and 60% in controls (P = 0.005). Light microscopy revealed severe progressive retinal degeneration in both groups. No histologic evidence of retinal toxicity was found in cat retina after subretinal injection of tissue plasminogen activator (50 micrograms/ml). Although treatment with tissue plasminogen activator accelerated the clearance of subretinal hemorrhage, it failed to prevent secondary retinal degeneration in this rabbit model.
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Florida.
M W
MW
Johnson
K R
KR
Olsen
E
E
Hernandez
D000818:Animals; D002415:Cats; D009887:Ophthalmoscopy; D011817:Rabbits; D011897:Random Allocation; D012162:Retinal Degeneration / Q000473:pathology / Q000517:prevention & control; D012166:Retinal Hemorrhage / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014463:Ultrasonography
D010959:Tissue Plasminogen Activator